PL3500564T3 - Inhibitory acylotransferazy diacyloglicerolu 2 - Google Patents
Inhibitory acylotransferazy diacyloglicerolu 2Info
- Publication number
- PL3500564T3 PL3500564T3 PL17761332T PL17761332T PL3500564T3 PL 3500564 T3 PL3500564 T3 PL 3500564T3 PL 17761332 T PL17761332 T PL 17761332T PL 17761332 T PL17761332 T PL 17761332T PL 3500564 T3 PL3500564 T3 PL 3500564T3
- Authority
- PL
- Poland
- Prior art keywords
- acylotranspherase
- inhibitors
- diacyl glycerol
- diacyl
- glycerol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377137P | 2016-08-19 | 2016-08-19 | |
| PCT/IB2017/054862 WO2018033832A1 (en) | 2016-08-19 | 2017-08-09 | Diacylglycerol acyltransferase 2 inhibitors |
| EP17761332.0A EP3500564B1 (en) | 2016-08-19 | 2017-08-09 | Diacylglycerol acyltransferase 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3500564T3 true PL3500564T3 (pl) | 2021-04-06 |
Family
ID=59762015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17761332T PL3500564T3 (pl) | 2016-08-19 | 2017-08-09 | Inhibitory acylotransferazy diacyloglicerolu 2 |
Country Status (44)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR109179A1 (es) * | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| AU2019211322A1 (en) | 2018-01-23 | 2020-07-23 | Gila Therapeutics, Inc. | Peptide YY pharmaceutical formulations, compositions, and methods |
| EP3765034A1 (en) | 2018-03-12 | 2021-01-20 | Yeda Research and Development Co. Ltd | Treatment of a heart disease |
| CA3045644C (en) | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| US11254660B2 (en) * | 2018-08-31 | 2022-02-22 | Pfizer Inc. | Combinations for treatment of NASH/NAFLD and related diseases |
| RU2706026C1 (ru) * | 2018-12-28 | 2019-11-13 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы | Способ лечения неалкогольной жировой болезни печени и сахарного диабета второго типа |
| WO2020234726A1 (en) | 2019-05-20 | 2020-11-26 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶２ 抑制劑 |
| US20240148679A1 (en) * | 2019-10-16 | 2024-05-09 | Ohio State Innovation Foundation | Methods and compositions related to treatment and prevention of cancer by inhibition of dgat1 and dgat2 |
| US20230045419A1 (en) | 2019-12-10 | 2023-02-09 | Pfizer Inc. | Solid Forms of 2-((4-((S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt |
| AU2020413583B2 (en) * | 2019-12-23 | 2023-12-14 | Lg Chem, Ltd. | Novel amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof |
| TWI762100B (zh) * | 2019-12-23 | 2022-04-21 | 南韓商Ｌｇ化學股份有限公司 | 新穎胺基芳基衍生物及其作為針對二醯基甘油醯基轉移酶２之抑制劑之用途 |
| ES2986788T3 (es) | 2020-02-07 | 2024-11-12 | Gasherbrum Bio Inc | Agonistas heterocíclicos de GLP-1 |
| WO2021161222A1 (en) * | 2020-02-11 | 2021-08-19 | Inorbit Therapeutics Ab | Compounds useful in inhibiting diacylglycerol o-acyltransferase and methods of making and using the same |
| JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| JP2022058085A (ja) * | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| MX2022010811A (es) | 2020-03-27 | 2022-09-27 | Pfizer | Tratamiento de la diabetes tipo 2 u obesidad o sobrepeso con el acido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piridin-2-il}piperidin -1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-bencimidazol-6-carboxil ico o una sal farmaceutica del mismo. |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| AR122092A1 (es) | 2020-05-18 | 2022-08-10 | Merck Sharp & Dohme | Inhibidores de diacilglicerol o-aciltransferasa 2 |
| LT4161927T (lt) | 2020-06-09 | 2024-09-25 | Pfizer Inc. | Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas |
| TWI817191B (zh) * | 2020-09-04 | 2023-10-01 | 南韓商Ｌｇ化學股份有限公司 | 新穎聯芳基衍生物及其作為針對二醯基甘油醯基轉移酶２之抑制劑之用途 |
| CN116685577A (zh) | 2020-10-08 | 2023-09-01 | 默沙东有限责任公司 | 作为新型二酰基甘油酯o-酰基转移酶2抑制剂的苯并咪唑酮衍生物的制备 |
| TW202229232A (zh) | 2020-10-08 | 2022-08-01 | 美商默沙東藥廠 | 作為新穎二醯基甘油酯o-醯基轉移酶2抑制劑之吲哚酮衍生物的製備 |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| CN112972654B (zh) * | 2021-03-05 | 2022-07-01 | 温州医科大学慈溪生物医药研究院 | Fgf21在制备治疗脑神经损伤的药物中的应用 |
| US20250066337A1 (en) | 2021-08-26 | 2025-02-27 | Pfizer Inc. | Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide |
| AU2022336407A1 (en) | 2021-08-31 | 2024-02-22 | Pfizer Inc. | Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| IL312296A (en) * | 2021-12-01 | 2024-06-01 | Pfizer | 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART |
| ES3039638T3 (en) | 2021-12-06 | 2025-10-23 | Pfizer | Melanocortin 4 receptor antagonists and uses thereof |
| EP4490155A1 (en) | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4508047A1 (en) | 2022-04-14 | 2025-02-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| CN115089590B (zh) * | 2022-06-13 | 2023-05-12 | 同济大学 | 环戊基三唑嘧啶类药物作为药物成分在肝炎药物中的应用 |
| EP4626881A1 (en) | 2022-12-02 | 2025-10-08 | Merck Sharp & Dohme LLC | Preparation of fused azole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors |
| WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| AU2024250528A1 (en) | 2023-04-14 | 2025-10-23 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2025099561A1 (en) | 2023-11-07 | 2025-05-15 | Pfizer Inc. | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2025141495A1 (en) | 2023-12-28 | 2025-07-03 | Pfizer Inc. | Novel method of preparing ervogastat |
| WO2025163561A1 (en) | 2024-02-01 | 2025-08-07 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| US20250326741A1 (en) | 2024-04-22 | 2025-10-23 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2025224648A1 (en) | 2024-04-26 | 2025-10-30 | Pfizer Inc. | Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| DK0580860T4 (da) | 1991-04-16 | 2005-03-21 | Nippon Shinyaku Co Ltd | Fremgangsmåde til fremstilling af en fast dispersion |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| DE69837903T2 (de) | 1997-08-11 | 2008-02-14 | Pfizer Products Inc., Groton | Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit |
| JP2002519380A (ja) | 1998-07-06 | 2002-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | 二元アンギオテンシン／エンドセリン・レセプタ拮抗剤としてのビフェニルスルホンアミド化合物 |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| IL157253A0 (en) | 2001-02-28 | 2004-02-19 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| EP1478437B1 (en) | 2002-02-27 | 2005-08-31 | Pfizer Products Inc. | Acc inhibitors |
| AU2005247684B2 (en) | 2004-05-12 | 2008-10-23 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors |
| UA84208C2 (en) | 2004-05-25 | 2008-09-25 | Пфайзер Продактс Инк. | Tetraazabenzo(e)azulene derivatives and analogs thereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| EP2010520B1 (en) | 2006-04-20 | 2012-09-12 | Pfizer Products Inc. | Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases |
| MX2009005604A (es) | 2006-11-29 | 2009-06-08 | Pfizer Prod Inc | Inhibidores espiro cetona de acetil-coa carboxilasa. |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| AU2008339570B2 (en) * | 2007-12-20 | 2012-04-12 | Astrazeneca Ab | Carbamoyl compounds as DGAT1 inhibitors 190 |
| ES2545231T3 (es) | 2008-05-28 | 2015-09-09 | Pfizer Inc. | Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa |
| WO2009144555A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| US20110130365A1 (en) | 2008-07-29 | 2011-06-02 | Benbow John W | Fluorinated Heteroaryls |
| MY155418A (en) | 2008-08-28 | 2015-10-15 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| AU2009333333A1 (en) | 2008-12-17 | 2011-06-30 | Via Pharmaceuticals, Inc | Inhibitors of diacylglycerol aclytransferase |
| WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| KR101295937B1 (ko) | 2009-03-11 | 2013-08-14 | 화이자 인코포레이티드 | 글루코카이네이즈 억제제로서 사용되는 벤조푸라닐 유도체 |
| US20120095028A1 (en) | 2009-03-20 | 2012-04-19 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| EP2427448A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
| GEP20135907B (en) | 2009-06-05 | 2013-08-12 | Pfizer | L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| KR102002198B1 (ko) | 2011-11-29 | 2019-07-19 | 제넨테크, 인크. | Lrrk2 조절제로서의 아미노피리미딘 유도체 |
| WO2013137628A1 (ko) | 2012-03-16 | 2013-09-19 | 한국생명공학연구원 | 신규한 디아실글리세롤 아실트랜스퍼레이즈 2 억제 물질 및 이의 이용 |
| MA37385B1 (fr) * | 2012-04-06 | 2019-09-30 | Pfizer Inc Etat De Delaware | Inhibiteurs de diacylglycérol-acyltransférase 2 |
| JP6165314B2 (ja) | 2013-03-15 | 2017-07-19 | デシフェラ ファーマシューティカルズ，エルエルシー | 抗癌活性及び抗増殖活性を呈する２−アミノピリミジン−６−オン及び類似体 |
| AR098394A1 (es) | 2013-11-25 | 2016-05-26 | Lilly Co Eli | Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2) |
| MX2016012008A (es) * | 2014-03-17 | 2016-12-07 | Pfizer | Inhibidores de diacilglicerol acil transferasa 2 para utilizarlos en el tratamiento de enfermedades metabolicas y relacionadas. |
| US9877957B2 (en) | 2014-09-05 | 2018-01-30 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
| WO2016036638A1 (en) | 2014-09-05 | 2016-03-10 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
| US10568876B2 (en) | 2014-09-05 | 2020-02-25 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
| AR109179A1 (es) * | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| US10017992B2 (en) | 2016-11-04 | 2018-07-10 | Ashmin Holding Llc | Radial ball bearing and method |
-
2017
- 2017-07-27 AR ARP170102125A patent/AR109179A1/es unknown
- 2017-08-09 AU AU2017313420A patent/AU2017313420B2/en active Active
- 2017-08-09 NZ NZ750412A patent/NZ750412A/en unknown
- 2017-08-09 EA EA201990202A patent/EA037476B1/ru unknown
- 2017-08-09 DK DK17761332.0T patent/DK3500564T3/da active
- 2017-08-09 SG SG11201900490WA patent/SG11201900490WA/en unknown
- 2017-08-09 MY MYPI2019000769A patent/MY196330A/en unknown
- 2017-08-09 GE GEAP201715005A patent/GEP20207159B/en unknown
- 2017-08-09 MA MA45985A patent/MA45985B1/fr unknown
- 2017-08-09 RS RS20201375A patent/RS61141B1/sr unknown
- 2017-08-09 PE PE2019000392A patent/PE20190518A1/es unknown
- 2017-08-09 JP JP2019508858A patent/JP6657473B2/ja active Active
- 2017-08-09 TN TNP/2019/000036A patent/TN2019000036A1/en unknown
- 2017-08-09 MX MX2019001872A patent/MX370766B/es active IP Right Grant
- 2017-08-09 PT PT177613320T patent/PT3500564T/pt unknown
- 2017-08-09 LT LTEP17761332.0T patent/LT3500564T/lt unknown
- 2017-08-09 SI SI201730499T patent/SI3500564T1/sl unknown
- 2017-08-09 ES ES17761332T patent/ES2834060T3/es active Active
- 2017-08-09 CN CN201780050709.4A patent/CN109641875B/zh active Active
- 2017-08-09 WO PCT/IB2017/054862 patent/WO2018033832A1/en not_active Ceased
- 2017-08-09 CR CR20190085A patent/CR20190085A/es unknown
- 2017-08-09 EP EP17761332.0A patent/EP3500564B1/en active Active
- 2017-08-09 RU RU2019104413A patent/RU2719589C1/ru active
- 2017-08-09 PH PH1/2019/500349A patent/PH12019500349B1/en unknown
- 2017-08-09 MD MDE20190711T patent/MD3500564T2/ro unknown
- 2017-08-09 CU CU2019000003A patent/CU24507B1/es unknown
- 2017-08-09 UA UAA201900751A patent/UA122100C2/uk unknown
- 2017-08-09 HR HRP20201748TT patent/HRP20201748T1/hr unknown
- 2017-08-09 PL PL17761332T patent/PL3500564T3/pl unknown
- 2017-08-09 HU HUE17761332A patent/HUE051731T2/hu unknown
- 2017-08-09 KR KR1020197007312A patent/KR102225925B1/ko active Active
- 2017-08-11 US US15/674,914 patent/US10071992B2/en active Active
- 2017-08-16 TW TW106127806A patent/TWI688560B/zh active
- 2017-08-16 CA CA2976690A patent/CA2976690C/en active Active
- 2017-08-17 UY UY0001037366A patent/UY37366A/es not_active Application Discontinuation
-
2018
- 2018-05-11 US US15/977,238 patent/US20180258081A1/en not_active Abandoned
-
2019
- 2019-01-24 ZA ZA201900516A patent/ZA201900516B/en unknown
- 2019-01-31 SV SV2019005823A patent/SV2019005823A/es unknown
- 2019-02-11 NI NI201900012A patent/NI201900012A/es unknown
- 2019-02-13 IL IL264818A patent/IL264818B/en active IP Right Grant
- 2019-02-14 CL CL2019000406A patent/CL2019000406A1/es unknown
- 2019-02-15 DO DO2019000032A patent/DOP2019000032A/es unknown
- 2019-02-18 CO CONC2019/0001421A patent/CO2019001421A2/es unknown
- 2019-02-20 EC ECSENADI201912670A patent/ECSP19012670A/es unknown
-
2020
- 2020-02-18 US US16/793,441 patent/US11034678B2/en active Active
- 2020-11-04 CY CY20201101042T patent/CY1123679T1/el unknown
-
2021
- 2021-06-11 US US17/345,064 patent/US11866425B2/en active Active
-
2023
- 2023-11-28 US US18/520,638 patent/US20240140937A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3500564T3 (pl) | Inhibitory acylotransferazy diacyloglicerolu 2 | |
| IL283639A (en) | Kif18a inhibitors | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| IL269196A (en) | Novel inhibitors | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| PL3710439T3 (pl) | Inhibitory kras g12c | |
| PL3468966T3 (pl) | Inhibitory interakcji menina-mll | |
| EP3541932A4 (en) | INHIBITORS OF CRISPR-CAS9 | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| EP3801503A4 (en) | INHIBITORS OF SARM1 | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| IL304348A (en) | Cd73 inhibitors | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| EP3801499A4 (en) | INHIBITORS OF SARM1 | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| EP3541820A4 (en) | MAGL INHIBITORS | |
| EP3541821A4 (en) | Magl inhibitors | |
| EP3541822A4 (en) | MAGL INHIBITORS | |
| EP3817736A4 (en) | PIKFYVE INHIBITORS | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| EP3804707A4 (en) | KINASE INHIBITOR | |
| EP3609882A4 (en) | Heterocyclic inhibitors of pcsk9 | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| MA46889A (fr) | Inhibiteurs de gsk-3 | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |